Volume 6, Issue 7

Advancing MS Care: Emerging Therapies and Molecular Targets

In this issue:

Multiple sclerosis (MS) is a chronic, often progressive disease impacting the central nervous system, leading to disability in millions of individuals worldwide. Novel approaches are continuously emerging to provide more targeted and effective treatment options. In this issue of eMultipleSclerosis Review, Cole Harrington, MD, PhD, Assistant Professor in Neurology at The Ohio State University Wexner Medical Center, and Nikhil Modak, MD, Neuroimmunology Fellow at The Ohio State University, discuss the latest therapeutic advancements in MS treatment. Key articles explore innovative approaches, including CD19-targeted CAR-T cell therapy as well as Bruton’s tyrosine kinase inhibitors, to reduce disability progression. Review of key studies highlight the evolving landscape of MS therapeutics targeting novel mechanisms to improve outcomes in both relapsing and progressive forms of the disease.

Learning objective:

Describe safety and efficacy of treatment for MS that are newly available or in development.  

Authors:

Cole Harrington, MD, PhD
Cole Harrington, MD, PhD

Assistant Professor in Neurology
Department of Neurology
The Ohio State University Wexner Medical Center
Columbus, OH

Nikhil Modak, MD
Nikhil Modak, MD

Neuroimmunology Fellow
The Ohio State University
Columbus, OH

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: December 17, 2024
Expiration date: December 16, 2026